IM-1021
- Generic Name
- IM-1021
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Phase 1
Recruiting
- Conditions
- Solid MalignanciesHematologic Malignancies
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Immunome, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT06823167
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸NEXT Oncology, Irving, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath